Where does combination therapy with an SGLT2 inhibitor plus a DPP-4 inhibitor fit in the management of type 2 diabetes?

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

17 citing papers in PubMed, 1 synthesis or guideline pooled it.

1. Efficacy and safety of combination therapy using SGLT2 and DPP4 inhibitors to treat type 2 diabetes: An updated systematic review and meta-analysis with focus on an Asian subpopulation.Diabetes, obesity & metabolism · 2025
   Pooled it
2. A randomized, placebo-controlled trial to assess the efficacy and safety of sitagliptin in Japanese patients with type 2 diabetes and inadequate glycaemic control on ipragliflozin.Diabetes, obesity & metabolism · 2021 · on this map
   Trial
3. Efficacy and safety of the addition of ertugliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin and sitagliptin: The VERTIS SITA2 placebo-controlled randomized study.Diabetes, obesity & metabolism · 2018 · on this map
   Trial
4. A 24-week study to evaluate the efficacy and safety of once-weekly dulaglutide added on to glimepiride in type 2 diabetes (AWARD-8).Diabetes, obesity & metabolism · 2016
   Trial
5. Evaluating the Efficacy, Safety, and Tolerability of Combination Therapy of Dapagliflozin and Linagliptin Over Dapagliflozin and Vildagliptin in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin.Cureus · 2024
   Article
6. Switching to Versus Addition of Incretin-Based Drugs Among Patients With Type 2 Diabetes Taking Sodium-Glucose Cotransporter-2 Inhibitors.Journal of the American Heart Association · 2022
   Observational
7. Predictors of the Therapeutic Efficacy and Consideration of the Best Combination Therapy of Sodium-Glucose Co-transporter 2 Inhibitors.Diabetes & metabolism journal · 2019
   Observational
8. Pharmacokinetic Characteristics and Clinical Efficacy of an SGLT2 Inhibitor Plus DPP-4 Inhibitor Combination Therapy in Type 2 Diabetes.Clinical pharmacokinetics · 2017
   Review
9. Saxagliptin/Dapagliflozin: A Review in Type 2 Diabetes Mellitus.Drugs · 2017
   Review
10. Empagliflozin: Role in Treatment Options for Patients with Type 2 Diabetes Mellitus.Diabetes therapy : research, treatment and education of diabetes and related disorders · 2017
    Review
11. Sodium-glucose cotransporter 2 inhibitors combined with dipeptidyl peptidase-4 inhibitors in the management of type 2 diabetes: a review of current clinical evidence and rationale.Drug design, development and therapy · 2017
    Review
12. Emerging use of combination therapies for the management of type 2 diabetes - focus on saxagliptin and dapagliflozin.Diabetes, metabolic syndrome and obesity : targets and therapy · 2017 · on this map
    Review
13. Effectiveness of long-term treatment with SGLT2 inhibitors: real-world evidence from a specialized diabetes center.Diabetology & metabolic syndrome · 2017
    Article
14. DPP-4 inhibitors, heart failure and type 2 diabetes: all eyes on safety.Cardiovascular diagnosis and therapy · 2015
    Article
15. Empagliflozin/Linagliptin: A Review in Type 2 Diabetes.Drugs · 2015
    Review
16. SGLT2 inhibitors: the latest "new kids on the block"!Diabetes care · 2015
    Article
17. A short-term follow-up of glycemic and body weight changes in diabetic patients who replaced dipeptidyl peptidase-4 inhibitors with the sodium-glucose cotransporter 2.Annals of Saudi medicine
    Article

Corrections and comments

• Comment on
  Dual add-on therapy in type 2 diabetes poorly controlled with metformin monotherapy: a randomized double-blind trial of saxagliptin plus dapagliflozin addition versus single addition of saxagliptin or dapagliflozin to metformin.2015

Authors and funding

1 author.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as